These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 9598479

  • 41. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine.
    Halling KC, King W, Sokolova IA, Karnes RJ, Meyer RG, Powell EL, Sebo TJ, Cheville JC, Clayton AC, Krajnik KL, Ebert TA, Nelson RE, Burkhardt HM, Ramakumar S, Stewart CS, Pankratz VS, Lieber MM, Blute ML, Zincke H, Seelig SA, Jenkins RB, O'Kane DJ.
    J Urol; 2002 May; 167(5):2001-6. PubMed ID: 11956427
    [Abstract] [Full Text] [Related]

  • 42. The dilemma of suspicious urine cytology in patients being followed for bladder cancer.
    Raitanen MP, Aine R, Kylmälä T, Kallio J, Liukkonen T, Tammela T, Finnbladder Group.
    Ann Chir Gynaecol; 2001 May; 90(4):256-9. PubMed ID: 11820413
    [Abstract] [Full Text] [Related]

  • 43. Urinary markers of bladder carcinoma.
    Dey P.
    Clin Chim Acta; 2004 Feb; 340(1-2):57-65. PubMed ID: 14734196
    [Abstract] [Full Text] [Related]

  • 44. Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer.
    Moonen PM, Kiemeney LA, Witjes JA.
    Eur Urol; 2005 Dec; 48(6):951-6; discussion 956. PubMed ID: 16257108
    [Abstract] [Full Text] [Related]

  • 45. Predictive values of urinary bladder tumor markers survivin and soluble-Fas comparison with cystoscopy and bladder tumor antigen.
    Ganas V, Kalaitzis C, Sountoulides P, Giannakopoulos S, Touloupidis S.
    Minerva Urol Nefrol; 2012 Dec; 64(4):279-85. PubMed ID: 23288215
    [Abstract] [Full Text] [Related]

  • 46. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology.
    Shariat SF, Casella R, Wians FH, Ashfaq R, Balko J, Sulser T, Gasser TC, Sagalowsky AI.
    Eur Urol; 2004 Mar; 45(3):304-13; author reply 313. PubMed ID: 15036675
    [Abstract] [Full Text] [Related]

  • 47. Patients with a negative cystoscopy and negative Nmp22® Bladderchek® test are at low risk of missed transitional cell carcinoma of the bladder: a prospective evaluation.
    Terrell JD, Elias KJ, Sagalowsky AI, Lotan Y.
    Int Braz J Urol; 2011 Mar; 37(6):706-11. PubMed ID: 22234001
    [Abstract] [Full Text] [Related]

  • 48. Urinary level of nuclear matrix protein 22 in the diagnosis of bladder cancer: experience with 130 patients with biopsy confirmed tumor.
    Casella R, Huber P, Blöchlinger A, Stoffel F, Dalquen P, Gasser TC, Lehmann K.
    J Urol; 2000 Dec; 164(6):1926-8. PubMed ID: 11061883
    [Abstract] [Full Text] [Related]

  • 49. Significance of the BTA test in bladder cancer: a multicenter trial. BTA Study Group Japan.
    Miyanaga N, Akaza H, Kameyama S, Hachiya T, Ozono S, Kuroda M, Koga H, Koiso K.
    Int J Urol; 1997 Nov; 4(6):557-60. PubMed ID: 9477183
    [Abstract] [Full Text] [Related]

  • 50. Diagnostic value of voided urine and bladder barbotage cytology in detecting transitional cell carcinoma of the urinary tract.
    Konety BR, Metro MJ, Melham MF, Salup RR.
    Urol Int; 1999 Nov; 62(1):26-30. PubMed ID: 10436427
    [Abstract] [Full Text] [Related]

  • 51. BTA TRAK urine test increases the efficacy of cytology in the diagnosis of low-grade transitional cell carcinoma of the bladder.
    Gibanel R, Ribal MJ, Filella X, Ballesta AM, Molina R, Alcaraz A, Alcover JB.
    Anticancer Res; 2002 Nov; 22(2B):1157-60. PubMed ID: 12168917
    [Abstract] [Full Text] [Related]

  • 52. Detection of recurrent bladder cancer: NMP22 test or urine cytology?
    Hosseini J, Golshan AR, Mazloomfard MM, Mehrsai AR, Zargar MA, Ayati M, Shakeri S, Jasemi M, Kabiri M.
    Urol J; 2012 Nov; 9(1):367-72. PubMed ID: 22395834
    [Abstract] [Full Text] [Related]

  • 53. The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer.
    Shariat SF, Casella R, Monoski MA, Sulser T, Gasser TC, Lerner SP.
    J Urol; 2003 Dec; 170(6 Pt 1):2244-7. PubMed ID: 14634389
    [Abstract] [Full Text] [Related]

  • 54. The BTA stat test: a tumor marker for the detection of upper tract transitional cell carcinoma.
    Walsh IK, Keane PF, Ishak LM, Flessland KA.
    Urology; 2001 Oct; 58(4):532-5. PubMed ID: 11597532
    [Abstract] [Full Text] [Related]

  • 55. [The use of NMP22 Bladder-Chek for the diagnosis and follow-up bladder cancer].
    Gonzalo Rodríguez V, Sanz Justo L, de Miguel Santamaría I, Martínez de Iturrate J, Fernández del Busto E.
    Arch Esp Urol; 2008 Apr; 61(3):377-84. PubMed ID: 18581675
    [Abstract] [Full Text] [Related]

  • 56. [The usefulness of urinary FDP in the diagnosis of bladder cancer: comparison with NMP22, BTA and cytology].
    Oeda T, Manabe D.
    Nihon Hinyokika Gakkai Zasshi; 2001 Jan; 92(1):1-5. PubMed ID: 11235137
    [Abstract] [Full Text] [Related]

  • 57. Urinary markers in the everyday diagnosis of bladder cancer.
    Dal Moro F, Valotto C, Guttilla A, Zattoni F.
    Urologia; 2013 Jan; 80(4):265-75. PubMed ID: 24419920
    [Abstract] [Full Text] [Related]

  • 58. Detection of bladder cancer using a point-of-care proteomic assay.
    Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y, Shen Y.
    JAMA; 2005 Feb 16; 293(7):810-6. PubMed ID: 15713770
    [Abstract] [Full Text] [Related]

  • 59. The Bard BTA test: its mode of action, sensitivity and specificity, compared to cytology of voided urine, in the diagnosis of superficial bladder cancer.
    Schamhart DH, de Reijke TM, van der Poel HG, Witjes JA, de Boer EC, Kurth K, Schalken JA.
    Eur Urol; 1998 Aug 16; 34(2):99-106. PubMed ID: 9693243
    [Abstract] [Full Text] [Related]

  • 60. BTA stat and BTA TRAK: A comparative evaluation of urine testing for the diagnosis of transitional cell carcinoma of the bladder.
    Irani J, Desgrandchamps F, Millet C, Toubert ME, Bon D, Aubert J, Le Duc A.
    Eur Urol; 1999 Feb 16; 35(2):89-92. PubMed ID: 9933800
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.